News
GSK bolts-on immuno-oncology candidate with €3.7bn Merck dea...
GlaxoSmithKline is making another big play in cancer, signing a wide-ranging deal with Merck KGaA for M7824, an immuno-oncology drug that made a splash at last year’s ESMO meeting.
